Top Markets
#1 Seeker Seeker +17.63%
#2 EXOD EXOD +9.04%
#3 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.48%
#4 aelf aelf +6.19%
#5 Solstice Solstice +5.55%
#6 Official Trump Official Trump +4.71%
#7 Derive Derive +4.46%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +4.18%
#9 Arowana Arowana +3.74%
#10 DexNet DexNet +3.67%
Coin of the day
Seeker Seeker
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Classifica tra le azioni #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Prezzo delle azioni
$64.97
Ultima sincronizzazione: 2024-05-20
Capitalizzazione di mercato
$1.97B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Alpine Immune Sciences, Inc. (ALPN)

Categoria

Healthcare
Ricavi di Alpine Immune Sciences, Inc. (ALPN)
Ricavi nel Mar 2024 TTM: $56.52M
Secondo gli ultimi rapporti finanziari di Alpine Immune Sciences, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $56.52M. Nel 2022, l'azienda ha registrato ricavi di $30.06M un aumento rispetto a i ricavi dell'anno 2021, che erano pari a $23.44M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Alpine Immune Sciences, Inc. da 2012 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $56.52M -4.00%
2023 $58.88M 95.84%
2022 $30.06M 28.24%
2021 $23.44M 151.13%
2020 $9.34M 436.49%
2019 $1.74M 146.81%
2018 $705.00K -59.27%
2017 $1.73M -41.32%
2016 $2.95M 499.59%
2015 $492.00K 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 22,235.59%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 10,553.19%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 27,755.71%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 3,841.90%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH